Jagsonpal Pharmaceuticals Ltd vs Sanofi Consumer Healthcare India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 209.5 as of 06 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 0 on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe P/E Ratio of Sanofi Consumer Healthcare India Ltd changed from 62.6 on December 2024 to 62.6 on December 2024 . This represents a CAGR of 0.00% over 1 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 0 crore on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe Market Cap of Sanofi Consumer Healthcare India Ltd changed from ₹ 11347 crore on December 2024 to ₹ 11347 crore on December 2024 . This represents a CAGR of 0.00% over 1 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Jun '26 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16% The revenue of Sanofi Consumer Healthcare India Ltd for the Mar '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 234.8 crore. This represent the decline of -100% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Jun '26 ebitda of ₹ 0 crore. This represent the growth of 9.2233718E16% The ebitda of Sanofi Consumer Healthcare India Ltd for the Mar '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 94.4 crore. This represent the decline of -100% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 9 quarters. This represents a CAGR of 24.71% The net profit of Sanofi Consumer Healthcare India Ltd changed from ₹ 62.7 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 0 % on December 2024 . This represents a CAGR of -100.00% over 7 yearsThe Dividend Payout of Sanofi Consumer Healthcare India Ltd changed from 6.06 % on December 2023 to 69.89 % on December 2024 . This represents a CAGR of 239.60% over 2 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Sanofi Consumer Healthcare India Ltd

Sanofi Consumer Healthcare India Limited was incorporated on May 10, 2023, as part of Sanofi's global strategy to establish a standalone Consumer Healthcare business.
This strategic move resulted in the demerger of the Consumer Healthcare business from Sanofi India Limited (SIL) into the Company through a Scheme of Arrangement, thereby creating a distinct legal entity.
The Scheme of Arrangement, which was sanctioned by the National Company Law Tribunal, Mumbai (NCLT) enabled the seamless transfer and vesting of all assets, liabilities, and operations of SIL to the Company. Pursuant to the Scheme becoming effective, the Consumer Healthcare Division (CHC) business of Sanofi India Limited (SIL) got demerged into the Company as a going concern through the Scheme of Arrangement and became effective from June 1, 2024.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Sanofi Consumer Healthcare India Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,406 Cr while Market cap of Sanofi Consumer Healthcare India Ltd is 10,728 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd?

As of May 6, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹209.5. On the other hand, Sanofi Consumer Healthcare India Ltd stock price is INR ₹4658.2.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Sanofi Consumer Healthcare India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.